Recorded fact · drug.label_indication

drug.label_indication for dimethyl-fumarate|multiple-sclerosis

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 16bbc80f resolves to.

The record

Fact id	`16bbc80fa25bff140f121a41`
Entity	drug: dimethyl-fumarate\|multiple-sclerosis
Field	drug.label_indication
Source	api.fda.gov
Read on	2026-11-10T19:02:47.536Z
Source version	openfda-label-20210713
Method	extract
Verification	verified
Licence	CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels
Edition	2026-11, Merkle root `006ab9a329709cbe...`

The verifying quote

Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Shown with dashes as hyphens. SHA-256 of the exact stored quote: 16b1e9d8222712f325da9b5a06120b032ebbc663f76b865af5317e5d8865ae91.

The value

{
 "ingredient": "Dimethyl Fumarate",
 "conditionId": "multiple-sclerosis",
 "conditionName": "Multiple Sclerosis",
 "matchedAlias": "multiple sclerosis",
 "context": "indication",
 "brand": "Dimethyl Fumarate",
 "identifiedVia": "generic_name",
 "extractor": 5,
 "labelSetId": "074d2820-6cb4-437a-8f6f-a21cb0a8ee02",
 "labelEffectiveTime": "20210713",
 "labelsRead": 16,
 "labelsNaming": 16,
 "registryEditionRoot": "1b44e76f5da1a417",
 "meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}

SHA-256 of the exact stored value: 46ff06d8afac30d0b619c03ecbe51cda7f3f2f749c5ee8bca2ca922f3a0ce5f9.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.